Zobrazeno 1 - 10
of 35
pro vyhledávání: '"T G Pokrovskaya"'
Autor:
P. R. Lebedev, E. V. Kuzubova, V. M. Pokrovsky, A. I. Radchenko, S. I. Osipyan, Yu. V. Stepenko, A. A. Apostol, L. M. Danilenko, A. A. Dolzhikov, T. G. Pokrovskaya, O. S. Gudyrev, Ya. S. Kochergina, O. V. Dudnikova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 12, Iss 1, Pp 63-73 (2024)
The aim of the work was to study the influence of the researcher on the muscle strength assessment in animals in the experiment by comparing the results of the automated “inverted grid” test and its classical variant.Materials and methods. Male l
Externí odkaz:
https://doaj.org/article/39c88513553f46e49012e4edc5c73089
Autor:
N. I Nesterova, V. V Pokrovskii, E. A Patrakhanov, I. V Pirozhkov, T. G Pokrovskaya, N. B Levit, I M.I, S. N. M. Kizi, A. V Nesterov, V. I Shutov, Y Yuri A. Hoshchenko
Publikováno v:
Archives of Razi Institute, Vol 76, Iss 4, Pp 1025-1034 (2021)
Sudden loss of blood flow to an area of the brain causes ischemic stroke, which leads to the loss of nerve function in the brain. The brain tissue leads to the death of brain cells in less than a few minutes due to the lack of oxygen and nutrients. T
Externí odkaz:
https://doaj.org/article/79963e54e3ac4afa875a18997ba257b3
Autor:
M. V. Korokin, V. O. Soldatov, A. A. Tietze, M. V. Golubev, A. E. Belykh, M. V. Kubekina, O. A. Puchenkova, T. A. Denisyuk, V. V. Gureyev, T. G. Pokrovskaya, O. S. Gudyrev, M. A. Zhuchenko, M. A. Zatolokina, M. V. Pokrovskiy
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 7, Iss 6, Pp 312-320 (2020)
The aim of the study was to test whether P-αB can be positioned as a preventing and treating agent for cardiovascular diseases.Materials and methods. The study was performed on sexually mature male Wistar rats. Endothelial dysfunction was modulated
Externí odkaz:
https://doaj.org/article/fb35357e78b640b7aca9ed89c2cf61da
Publikováno v:
Кубанский научный медицинский вестник, Vol 25, Iss 6, Pp 73-77 (2018)
Aim. The research was designed to study the renoprotective properties of erythropoietin derivatives on the kidney ischemiareperfusion experimental model.Materials and methods. The renoprotective properties of asialo erythropoietin (0.4 μg/kg and 2.4
Externí odkaz:
https://doaj.org/article/02c192b2cb1940dba236420c3bc9a48e
Autor:
A. M. Lila, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshet’ko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, E. V. Kunder, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, P. S. Pukhtinskaya
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 3, Pp 293-301 (2018)
The paper gives data on the clinical efficiency and safety profile of long-term use of the infliximab (INF) biosimilar BCD-055 versus the reference drug Remicade® (REM) in a population of patients with active ankylosing spondylitis (AS).Subjects and
Externí odkaz:
https://doaj.org/article/f2ab7d59b1704636a39acc713ecb7947
Autor:
D. E. Karateev, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, A. M. Pristrom, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, U. V. Usacheva
Publikováno v:
Современная ревматология, Vol 11, Iss 3, Pp 14-25 (2017)
This article presents results from two clinical trials of infliximab biosimilar, BCD-055, including comparative data on the pharmacokinetics (PK), efficacy and safety of BCD-055 and innovator infliximab (IFX) in patients with ankylosing spondylitis (
Externí odkaz:
https://doaj.org/article/305ff993592e47ac835d9cdc1c914e7b
Autor:
E. L. Nasonov, V. I. Mazurov, E. V. Zonova, L. A. Knyazeva, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, Yu. S. Shapovalova, E. P. Ilivanova, D. G. Krechikova, N. A. Petrochenkova, O. V. Reshetko, L. N. Denisov, I. G. Gordeev, A. F. Davydova, N. A. Eremina, E. V. Zemerova, T. B. Ivanova, A. A. Kastanayan, T. G. Pokrovskaya, S. A. Smakotina, E. A. Smolyarchuk, A. V. Artemyeva, R. A. Ivanov, Yu. V. Usacheva, E. V. Chernyaeva
Publikováno v:
Научно-практическая ревматология, Vol 55, Iss 4, Pp 351-359 (2017)
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is a biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there has bee
Externí odkaz:
https://doaj.org/article/b1c240855964421db5640cb92522328f
Autor:
T. A. Denisuk, M. V. Pokrovskii, O. V. Philippova, A. A. Dolshikov, T. G. Pokrovskaya, M. V. Korokin, T. V. Avtina, O. A. Osipova
Publikováno v:
Кубанский научный медицинский вестник, Iss 3, Pp 46-51 (2016)
The use of inhibitors of HMG-Co-A reductase inhibitor simvastatin, atorvastatin, rosuvastatin and nanoparticulative rosuvastatin on background modeling endotoksininducing pathology, introduction of strain 603 Staphylococcusaureus leads to the develop
Externí odkaz:
https://doaj.org/article/2644ba072db746659cd14eca662e8162
Autor:
T. A. Denisyuk, M. V. Pokrovsky, O. V. Filippova, A. A. Dolzhikov, T. G. Pokrovskaya, M. V. Korokin, O. A. Osipova, A. I. Lazarev, G. A. Lazareva
Publikováno v:
Кубанский научный медицинский вестник, Iss 2, Pp 64-67 (2016)
Using the combined of L-arginine with inhibitors of HMG-Co-A reductase simvastatin, atorvastatin, rosuvastatin and rosuvastatin nanopartikulirovannym on background modeling endotoxin-induced disease, the introduction of strain 603 Staphylococcusaureu
Externí odkaz:
https://doaj.org/article/61fcb77c1b614769add6c774c92140a1
Autor:
T. A. Denisyuk, M. V. Pokrovsky, G. A. Lazareva, T. G. Pokrovskaya, M. V. Korokin, O. A. Osipova, A. I. Lazarev, L. N. Sernov, S. A. Demchenko
Publikováno v:
Кубанский научный медицинский вестник, Iss 1, Pp 30-34 (2016)
Using of the combined use of non-selective inhibitor of arginase L-norvaline with simvastatin, atorvastatin, rosuvastatin and rosuvastatin nanopartikulirovanny on background modeling endotoxin-induced disease, the introduction of strain 603 Staphyloc
Externí odkaz:
https://doaj.org/article/a0349a37d2be434a88ebed974ee9d8c4